Juan Gallego, MD
Psychiatry · Glen Oaks, NYNPI 1043473317
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,500 of the $8,117 with a category attached, or 80.1%. Alkermes, Inc. accounts for 95.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $7,863 and has fallen 99.4% since, to $46 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 18 payments — averaging $450.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$8K
- Neurocrine Biosciences, Inc.$185
- Biogen$90
- Novo Nordisk$66
- Sage Therapeutics, LLC$37
Across 10 payments — averaging $2799.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$28K
What the payments were for
- Consulting fees$6,50080%
- Travel & lodging$78010%
- Food & beverage$83710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 12 | $7,740 |
| Neurocrine Biosciences, Inc. | 3 | $185 |
| Biogen | 1 | $90 |
| Novo Nordisk | 1 | $66 |
| Sage Therapeutics, LLC | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$27,463
- ARISTADA INITIO$6,866
- INGREZZA$124
How this compares
$8,117 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clozapine | 14 | $382 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Glen Oaks
- Christoph CorrellGlen Oaks$1.5M
- John KaneGlen Oaks$817K
- Youssef HassounGlen Oaks$233K
- Jose Rubio-LorenteGlen Oaks$106K
- Delbert RobinsonGlen Oaks$83K
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Manish ZinzuvadiaNew York$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.